Overview

Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure

Status:
Not yet recruiting

Trial end date:
2024-08-30

Target enrollment:

Participant gender:

Summary

To investigate whether an early supported discharge strategy for patients admitted to hospital because of HF, using a pH neutral subcutaneous (SC) furosemide formulation (SQINFurosemide) at home (delivered by non-CE marked SQINInfusor), compared to a usual care strategy with intravenous (IV) furosemide in hospital, results in an increased number of days spent alive and out of hospital (DAOH) at 30 days.

Phase:

Phase 2

Details

Lead Sponsor:

NHS Greater Glasgow and Clyde

Collaborator:

University of Glasgow

Treatments:

Furosemide